Find and Pitch Jounalists, Get Your Story Covered

Tags: Consumer / Employer, Daily, Health Tech, SYN, Top Story leadership pharma Boehringer Ingelheim Zeiss

	Profile	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Merck is broadening its pipeline as Keytruda’s patent cliff looms - 8 days ago Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - about 2 months ago Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s - 3 months ago How Roche plans to fill a projected $8B sales gap - 4 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 8 months ago Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim - 10 months ago
2	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Merck is a new year outlier with its diabetes drug - 19 days ago Sanofi pours $1 billion into China for insulin plant - about 2 months ago Versant enters obesity with new startup - 2 months ago Lilly has more positive data on its weekly insulin - 5 months ago The biotech news you missed this week - 7 months ago Novartis is building a new radioligand plant in China - about 1 year ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 2 months ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 6 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 10 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a CEO change at AbbVie, a long-acting HIV drug, and more - 11 months ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - 12 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 12 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - about 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - about 1 year ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - about 1 year ago STAT+: Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility - about 1 year ago STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish - about 1 year ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - about 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - about 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses - over 1 year ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Pharma giants vie for oral GLP-1R approval - about 2 months ago Boehringer Ingelheim’s survodutide shows promise in liver fibrosis treatment - 8 months ago
5	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model - about 2 months ago Walgreens inks GLP-1 clinical trial deal with major German drugmaker - 9 months ago
6	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	This is Huge News For Eli Lilly Investors - 3 months ago Did Eli Lilly Just Get a Leg Up on Novo Nordisk? - 6 months ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	BioMarin’s big day today - 5 months ago STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation - about 1 year ago
8	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	Oncimmune announces new contract with global pharma company - 5 months ago
9	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market - 10 months ago
10	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Merck’s next big thing is (probably) on the way - 10 months ago Bayer, short on cash, reaches into shareholders’ pockets - 11 months ago Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis - about 1 year ago

Journalists covering Boehringer Ingelheim